Sonoma Pharmaceuticals
SNOA
20 hedge funds and large institutions have $1.56M invested in Sonoma Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 0 closing their positions.
18% more capital invested
Capital invested by funds: $1.32M → $1.56M (+$241K)
18% more funds holding
Funds holding: 17 → 20 (+3)
0.08% more ownership
Funds ownership: 0.43% → 0.51% (+0.08%)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$237K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$68.1K |
| 3 |
HSA
Hussman Strategic Advisors
Ellicott City,
Maryland
|
+$24.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$15.7K |
| 5 |
BA
Bard Associates
Chicago,
Illinois
|
+$1.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$52.3K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$6.12K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.12K |
| 4 |
BlackRock
New York
|
-$4.39K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.26K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $677K | -$52.3K | -333 | -7% |
|
|
BA
2
Bard Associates
Chicago,
Illinois
| $341K | +$1.57K | +10 | +0.4% |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $221K | +$237K | +1,509 | New |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $205K | +$68.1K | +434 | +45% |
|
|
5
Acadian Asset Management
Boston,
Massachusetts
| $38K | -$6.12K | -39 | -13% |
|
|
HSA
6
Hussman Strategic Advisors
Ellicott City,
Maryland
| $23K | +$24.3K | +155 | New |
|
|
7
BlackRock
New York
| $21K | -$4.39K | -28 | -16% |
|
|
8
UBS Group
Zurich,
Switzerland
| $15K | +$15.7K | +100 | New |
|
|
RE
9
RBC Europe
London,
United Kingdom
| $8.16K | – | – | – |
|
10
US Bancorp
Minneapolis,
Minnesota
| $4K | – | – | – |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $1K | -$6.12K | -39 | -89% |
|
12
Osaic Holdings
Scottsdale,
Arizona
| $1K | -$1.1K | -7 | -47% |
|
13
Morgan Stanley
New York
| $1K | – | – | – |
|
|
14
Bank of America
Charlotte,
North Carolina
| – | -$1.26K | -8 | -73% |
|
SNOA Hedge Fund Activity: Q2 2021 in Review
20 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q2 2021, worth a combined $1.56M — up 18% from $1.32M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SNOA positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $237K. The largest seller was Renaissance Technologies, cutting an estimated $52.3K.
- 20 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q2 2021, up from 17 in Q1 2021.
- Funds reported $1.56M of Sonoma Pharmaceuticals stock for Q2 2021, up 18% quarter-over-quarter.
- 3 funds opened new Sonoma Pharmaceuticals positions in Q2 2021 and 0 closed out, a net change of +3 holders.
- The largest Sonoma Pharmaceuticals buyer in Q2 2021 was Geode Capital Management, an estimated $237K added.
- The largest Sonoma Pharmaceuticals seller in Q2 2021 was Renaissance Technologies, an estimated $52.3K sold.
Based on aggregated 13F filings for Q2 2021.